Clinical Applications of Noncoding RNAs in Cancer

Clinical Applications of Noncoding RNAs in Cancer summarizes the existing strategies, advances, and future opportunities on the role of noncoding RNAs in cancer patients. Established clinicians and researchers from all around the world share their views and expertise and provide readers with invaluable knowledge on the subject. This book provides a comprehensive collection of information on the utility of noncoding RNAs in the diagnosis, prognosis, and therapy of cancer. It also discusses the evolutionary significance of noncoding RNAs and how the molecular tools such as RNA-seq, RNA-FISH, ic-SHAPE, and quantitative real-time PCR help in the detection and elucidation of the functions of noncoding RNAs. Additionally, the challenges associated with noncoding RNA approaches and future developments are discussed. It is a valuable resource for cancer researchers, oncologists, clinicians, and other biomedical field members who want to learn more about noninvasive ways to diagnose and efficiently treat diverse cancer types.

Dr. Subash Chandra Gupta is an additional professor and Head at the Department of Biochemistry, All India Institute of Medical Sciences, Guwahati, India. He is currently on lien from Banaras Hindu University, Varanasi, India. Dr. Gupta did his postdoctoral training from the Ohio State University and the University of Texas MD Anderson Cancer Center in the United States. Before joining the Banaras Hindu University, Dr. Gupta was an instructor at the University of Mississippi Medical Center in the United States. His current research is focused on uncovering the mechanism by which acidic microenvironment promote cancer growth. He is also working on cancer chemoprevention and on projects to elucidate the role of inflammatory pathways, cancer stem cells, exosomal microRNAs, and long noncoding RNAs in regulating tumor development. He has published over 100 peer-reviewed articles in highly prestigious journals. He has been honored with prestigious national and international awards. He has coedited special issues of scientific journals and three prestigious books. Currently he is an editorial board member on several scientific journals and an active reviewer on more than 80 journals.

Dr. Kishore B. Challagundla is an assistant professor in the Department of Biochemistry and Molecular Biology, the Children’s Health Research Institute, and a member of the NCI-designated Fred & Pamela Buffet Cancer Center at the University of Nebraska Medical Center in Omaha, NE, United States. Dr. Challagundla earned a master’s in Biochemistry from Bharathidasan University and a PhD in Biochemistry from the University of Lucknow, followed by postdoctoral training at the Mayo Clinic in Rochester, Minnesota Oregon Health & Science University in Portland, Oregon, and Children's Hospital Los Angeles in California. Challagundla 's lab research focuses on investigating the involvement of novel noncoding RNAs in therapy resistance, the role of exosomes in the cross-talk between tumor, microenvironment, and immune cells, the posttranslational modifications of immune checkpoint molecules by ubiquitination, and their potential role in escaping immune surveillance, the development of RNA-based diagnostic, prognostic, and therapy response predictive specific noninvasive biomarkers in body fluids, and the development of novel combination therapeutic strategies that maximize drug response without any toxicity in patients with high-risk neuroblastoma. Dr. Challagundla served as the principal investigator of several grants, including NIH, foundation, and institutional grants. Dr. Challagundla is an ad hoc reviewer to various national and international organizations such as NIH, Yorkshire Cancer Research (UK), University Grants Committee (Hong Kong), Dutch Cancer Society (The Netherlands), The Netherlands Organisation for Scientific Research (The Netherlands), Worldwide Cancer Research, The Indonesian Science Fund, The National Science Centre (Poland), The French National Cancer Institute (France), The Israel Science Foundation (Israel), Czech Science Foundation (Czech Republic), and The Natural Sciences and Engineering Research Council of Canada. Furthermore, Challagundla is an associate editor of various journals such as Molecular Therapy Nucleic Acids (Cell Press), Molecular Therapy Oncolytics (Cell press), PLoS One, BMC Molecular & Cellular Biology, Cancer Cell International, and an editorial board member of Cancers, The Journal of Extracellular Vesicles, and an active reviewer for more than 100 top international journals. Challagundla has published over 40 peer-reviewed articles in high-impact journals, written several book chapters, and is a recipient of various national and international awards.